PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects. A 52-week randomized controlled factorial study in subjects with IFG and/or IGT. Amendment 2007: PRESERVE TRIAL Pancreatic beta-cell dysfunction REStorEd by Valsartan Effects: A 26-week randomized controlled study in subjects with IFG and/or IGT.Amendment 2007: In stead of two medicaments (Rosiglitazon and valsartan), only valsartan has been completed. Due to negative publicity, Rosiglitazon was stopped. Target number of participant is thereby decreased from 144 to 80. The therapy duration is changed to 26 weeks instead of 52.

VU University Medical Center,AmsterdamThe Netherlands0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

•Male and female subjects (aged 35-70 years) with impaired fasting glucose (IFG; fasting plasma glucose 6.1 or higher and less than 7.0 mmol/l) and/or subjects with IFG (fasting plasma glucose 5.6 or higher and less than 7.0 mmol/l) ánd a family history of DM2 (i.e. first and second degree (i.e. grandparents) relatives), and/or impaired glucose tolerance (IGT; 2-h plasma glucose during 75-g oral glucose tolerance test 7.8-11.1 mmol/l) are eligible.

•1. Current use of ACE-I, ARB and/or TZDs and inability to discontinue these drugs;

发起方

VU University Medical Center,AmsterdamThe Netherlands